Literature DB >> 16926428

Critical role of type 1 cytokines in controlling initial infection with Burkholderia mallei.

Caroline A Rowland1, Ganjana Lertmemongkolchai, Alison Bancroft, Ashraful Haque, M Stephen Lever, Kate F Griffin, Matthew C Jackson, Michelle Nelson, Anne O'Garra, Richard Grencis, Gregory J Bancroft, Roman A Lukaszewski.   

Abstract

Burkholderia mallei is a gram-negative bacterium which causes the potentially fatal disease glanders in humans; however, there is little information concerning cell-mediated immunity to this pathogen. The role of gamma interferon (IFN-gamma) during B. mallei infection was investigated using a disease model in which infected BALB/c mice normally die between 40 and 60 days postinfection. IFN-gamma knockout mice infected with B. mallei died within 2 to 3 days after infection, and there was uncontrolled bacterial replication in several organs, demonstrating the essential role of IFN-gamma in the innate immune response to this pathogen. Increased levels of IFN-gamma, interleukin-6 (IL-6), and monocyte chemoattractant protein 1 were detected in the sera of immunocompetent mice in response to infection, and splenic mRNA expression of IFN-gamma, IL-6, IL-12p35, and IL-27 was elevated 24 h postinfection. The effects of IL-18, IL-27, and IL-12 on stimulation of the rapid IFN-gamma production were investigated in vitro by analyzing IFN-gamma production in the presence of heat-killed B. mallei. IL-12 was essential for IFN-gamma production in vitro; IL-18 was also involved in induction of IFN-gamma, but IL-27 was not required for IFN-gamma production in response to heat-killed B. mallei. The main cellular sources of IFN-gamma were identified in vitro as NK cells, CD8+ T cells, and TCRgammadelta T cells. Our data show that B. mallei is susceptible to cell-mediated immune responses which promote expression of type 1 cytokines. This suggests that development of effective vaccines against glanders should target the production of IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16926428      PMCID: PMC1594859          DOI: 10.1128/IAI.02046-05

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  IL-18 promotes type 1 cytokine production from NK cells and T cells in human intracellular infection.

Authors:  V E García; K Uyemura; P A Sieling; M T Ochoa; C T Morita; H Okamura; M Kurimoto; T H Rea; R L Modlin
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

2.  IL-18 contributes to host resistance against infection with Cryptococcus neoformans in mice with defective IL-12 synthesis through induction of IFN-gamma production by NK cells.

Authors:  K Kawakami; Y Koguchi; M H Qureshi; A Miyazato; S Yara; Y Kinjo; Y Iwakura; K Takeda; S Akira; M Kurimoto; A Saito
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

3.  Mouse model of sublethal and lethal intraperitoneal glanders (Burkholderia mallei).

Authors:  D L Fritz; P Vogel; D R Brown; D Deshazer; D M Waag
Journal:  Vet Pathol       Date:  2000-11       Impact factor: 2.221

4.  The hamster model of intraperitoneal Burkholderia mallei (glanders).

Authors:  D L Fritz; P Vogel; D R Brown; D M Waag
Journal:  Vet Pathol       Date:  1999-07       Impact factor: 2.221

5.  Elevated plasma concentrations of interferon (IFN)-gamma and the IFN-gamma-inducing cytokines interleukin (IL)-18, IL-12, and IL-15 in severe melioidosis.

Authors:  F N Lauw; A J Simpson; J M Prins; M D Smith; M Kurimoto; S J van Deventer; P Speelman; W Chaowagul; N J White; T van der Poll
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

6.  Bystander activation of CD8+ T cells contributes to the rapid production of IFN-gamma in response to bacterial pathogens.

Authors:  G Lertmemongkolchai; G Cai; C A Hunter; G J Bancroft
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

7.  Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection.

Authors:  B M Saunders; A A Frank; I M Orme; A M Cooper
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

8.  Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection.

Authors:  K Ohkusu; T Yoshimoto; K Takeda; T Ogura; S Kashiwamura; Y Iwakura; S Akira; H Okamura; K Nakanishi
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

9.  Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei.

Authors:  P Santanirand; V S Harley; D A Dance; B S Drasar; G J Bancroft
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

10.  Cure of progressive murine leishmaniasis: interleukin 4 dominance is abolished by transient CD4(+) T cell depletion and T helper cell type 1-selective cytokine therapy.

Authors:  F P Heinzel; R M Rerko
Journal:  J Exp Med       Date:  1999-06-21       Impact factor: 14.307

View more
  20 in total

1.  A Burkholderia pseudomallei deltapurM mutant is avirulent in immunocompetent and immunodeficient animals: candidate strain for exclusion from select-agent lists.

Authors:  Katie L Propst; Takehiko Mima; Kyoung-Hee Choi; Steven W Dow; Herbert P Schweizer
Journal:  Infect Immun       Date:  2010-04-19       Impact factor: 3.441

2.  MyD88-dependent recruitment of monocytes and dendritic cells required for protection from pulmonary Burkholderia mallei infection.

Authors:  Andrew Goodyear; Ryan Troyer; Helle Bielefeldt-Ohmann; Steven Dow
Journal:  Infect Immun       Date:  2011-10-24       Impact factor: 3.441

3.  Protection from pneumonic infection with burkholderia species by inhalational immunotherapy.

Authors:  Andrew Goodyear; Lisa Kellihan; Helle Bielefeldt-Ohmann; Ryan Troyer; Katie Propst; Steven Dow
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

Review 4.  The emerging role of autoimmunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/cfs).

Authors:  Gerwyn Morris; Michael Berk; Piotr Galecki; Michael Maes
Journal:  Mol Neurobiol       Date:  2013-09-26       Impact factor: 5.590

5.  Critical protective role for MCP-1 in pneumonic Burkholderia mallei infection.

Authors:  Andrew Goodyear; Abby Jones; Ryan Troyer; Helle Bielefeldt-Ohmann; Steven Dow
Journal:  J Immunol       Date:  2009-12-30       Impact factor: 5.422

6.  Proteomic Analysis of Non-human Primate Peripheral Blood Mononuclear Cells During Burkholderia mallei Infection Reveals a Role of Ezrin in Glanders Pathogenesis.

Authors:  Chih-Yuan Chiang; Yang Zhong; Michael D Ward; Douglas J Lane; Tara Kenny; Raysa Rosario-Acevedo; Brett P Eaton; Sylvia R Treviño; Taylor B Chance; Meghan Hu; Patricia L Worsham; David M Waag; Richard T Moore; Lisa H Cazares; Christopher K Cote; Yingyao Zhou; Rekha G Panchal
Journal:  Front Microbiol       Date:  2021-04-22       Impact factor: 5.640

7.  Bystander T cells in human immune responses to dengue antigens.

Authors:  Duangchan Suwannasaen; Arunrat Romphruk; Chanvit Leelayuwat; Ganjana Lertmemongkolchai
Journal:  BMC Immunol       Date:  2010-09-20       Impact factor: 3.615

Review 8.  Development of Burkholderia mallei and pseudomallei vaccines.

Authors:  Ediane B Silva; Steven W Dow
Journal:  Front Cell Infect Microbiol       Date:  2013-03-11       Impact factor: 5.293

9.  Host immunity in the protective response to vaccination with heat-killed Burkholderia mallei.

Authors:  Gregory C Whitlock; Roman A Lukaszewski; Barbara M Judy; Slobodan Paessler; Alfredo G Torres; D Mark Estes
Journal:  BMC Immunol       Date:  2008-09-29       Impact factor: 3.615

10.  Inactivation of [Fe-S] metalloproteins mediates nitric oxide-dependent killing of Burkholderia mallei.

Authors:  Jessica Jones-Carson; James Laughlin; Mohammed A Hamad; Amanda L Stewart; Martin I Voskuil; Andrés Vázquez-Torres
Journal:  PLoS One       Date:  2008-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.